<p>Eton Pharmaceuticals, Inc.（納斯達克代碼：ETON - 獲取免費報告）在覆蓋該公司的五位分析師中獲得了 “持有” 的共識推薦，Marketbeat 報道。兩位股票研究分析師給予該股票 “賣出” 評級，三位分析師給予 “買入” 評級。在過去一年中，給予該股票評級的分析師的平均一年目標價為 29.6667 美元。</p>
<p>獲取 <strong>Eton Pharmaceuticals</strong> 的提醒：</p>
<p>最近，一些分析師對 ETON 股票發表了評論。Zacks Research 在 11 月 13 日的研究報告中將 Eton Pharmaceuticals 的評級從 “持有” 下調至 “強烈賣出”。Weiss Ratings 在 10 月 8 日的報告中重申了對 Eton Pharmaceuticals 股票的 “賣出（d-）” 評級。最後，Wall Street Zen 在 12 月 13 日的報告中將 Eton Pharmaceuticals 的股票評級從 “買入” 下調至 “持有”。</p>
<p><strong>查看我們對 ETON 的最新分析</strong></p>
<h2>Eton Pharmaceuticals 的機構交易</h2>
<p>一些機構投資者和對沖基金最近買入和賣出了該股票的股份。阿拉斯加州財政部在第三季度新購入了 Eton Pharmaceuticals 的股份，價值約 30,000 美元。Ameritas Investment Partners Inc. 在第二季度新購入了 Eton Pharmaceuticals 的股份，價值約 37,000 美元。Quarry LP 在第三季度新購入了 Eton Pharmaceuticals 的股份，價值約 37,000 美元。Legal &amp; General Group Plc 在第二季度新購入了 Eton Pharmaceuticals 的股份，價值約 41,000 美元。最後，AlphaQuest LLC 在第一季度新購入了 Eton Pharmaceuticals 的股份，價值約 53,000 美元。目前，27.86% 的股票由機構投資者和對沖基金持有。</p>
<h2>Eton Pharmaceuticals 股票表現</h2>
<p>納斯達克 ETON 週二開盤價為 16.57 美元。該公司的 50 日移動平均價格為 17.21 美元，200 日移動平均價格為 16.76 美元。該股票的市值為 4.4441 億美元，市盈率為-66.28，貝塔值為 1.17。該公司的債務與股本比率為 1.19，速動比率為 1.25，流動比率為 1.63。Eton Pharmaceuticals 的 52 周低點為 11.09 美元，52 周高點為 23.00 美元。</p>
<p>Eton Pharmaceuticals（納斯達克代碼：ETON - 獲取免費報告）最近於 11 月 6 日發佈了季度財報。該公司報告的每股收益為（0.07）美元，低於共識預期的 0.13 美元（差距為 0.20 美元）。該公司季度收入為 2246 萬美元，而分析師預期為 2047 萬美元。Eton Pharmaceuticals 的淨利潤率為-9.50%，股本回報率為-11.32%。平均而言，股票分析師預計 Eton Pharmaceuticals 在當前財政年度將發佈-0.14 的每股收益。</p>
<h2>Eton Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Eton Pharmaceuticals, Inc 是一家專注於開發、生產和商業化針對罕見和服務不足疾病的仿製藥和專有藥品的專業製藥公司。公司總部位於佛羅里達州西棕櫚灘，利用其在激素療法和複雜分子方面的專業知識，解決患者需求高、競爭有限的治療領域。自 2016 年成立以來，Eton 一直致力於建立一個多元化的產品組合，將成熟的仿製藥與針對性品牌產品相結合。</p>
<p>該公司的產品線包括甲狀腺激素替代品，如干燥甲狀腺和利奧甲狀腺素，以及用於弓形蟲病的吡美莫司片。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Eton Pharmaceuticals</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者提醒：微型 “3 美元人工智能奇蹟股票” 即將爆發</li>
<li>資本利得税是否可以扣除任何費用？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>最後的黃金牛市</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVRPTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVRPTg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Eton Pharmaceuticals 嗎？</h2>
<p>在考慮 Eton Pharmaceuticals 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前立即購買……而 Eton Pharmaceuticals 並不在名單上。</p>
<p>雖然 Eton Pharmaceuticals 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ETON

<p>Eton Pharmaceuticals, Inc.（納斯達克代碼：ETON）獲得了五位分析師的共識 “持有” 評級。兩位分析師給予 “賣出” 評級，三位給予 “買入” 評級。平均一年目標價為 29.67 美元。最近的分析師行動包括 Zacks Research 將評級下調至 “強烈賣出”，Wall Street Zen 則維持 “持有” 評級。機構投資者持有該股票 27.86%。公司報告了第三季度的虧損，未能達到預期。Eton 專注於罕見疾病治療，並擁有多樣化的產品組合</p>

<p>Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) has been given a consensus recommendation of &#34;Hold&#34; by the five analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $29.6667.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals, Inc.（納斯達克代碼：ETON - 獲取免費報告）在覆蓋該公司的五位分析師中獲得了 “持有” 的共識推薦，Marketbeat 報道。兩位股票研究分析師給予該股票 “賣出” 評級，三位分析師給予 “買入” 評級。在過去一年中，給予該股票評級的分析師的平均一年目標價為 29.6667 美元。</p>
</div><p>Get <strong>Eton Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Eton Pharmaceuticals</strong> 的提醒：</p>
</div><p>A number of analysts have recently commented on ETON shares. Zacks Research lowered Eton Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Thursday, November 13th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Eton Pharmaceuticals in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Eton Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, December 13th.</p>
<div class="lb-trans"><p>最近，一些分析師對 ETON 股票發表了評論。Zacks Research 在 11 月 13 日的研究報告中將 Eton Pharmaceuticals 的評級從 “持有” 下調至 “強烈賣出”。Weiss Ratings 在 10 月 8 日的報告中重申了對 Eton Pharmaceuticals 股票的 “賣出（d-）” 評級。最後，Wall Street Zen 在 12 月 13 日的報告中將 Eton Pharmaceuticals 的股票評級從 “買入” 下調至 “持有”。</p>
</div><p><strong>Check Out Our Latest Analysis on ETON</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ETON 的最新分析</strong></p>
</div><h2>Institutional Trading of Eton Pharmaceuticals</h2>
<div class="lb-trans"><h2>Eton Pharmaceuticals 的機構交易</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State of Alaska Department of Revenue acquired a new position in Eton Pharmaceuticals during the 3rd quarter worth about $30,000. Ameritas Investment Partners Inc. bought a new position in shares of Eton Pharmaceuticals during the second quarter worth about $37,000. Quarry LP bought a new position in shares of Eton Pharmaceuticals during the third quarter worth about $37,000. Legal &amp; General Group Plc acquired a new position in shares of Eton Pharmaceuticals in the second quarter worth approximately $41,000. Finally, AlphaQuest LLC bought a new stake in Eton Pharmaceuticals in the first quarter valued at approximately $53,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近買入和賣出了該股票的股份。阿拉斯加州財政部在第三季度新購入了 Eton Pharmaceuticals 的股份，價值約 30,000 美元。Ameritas Investment Partners Inc. 在第二季度新購入了 Eton Pharmaceuticals 的股份，價值約 37,000 美元。Quarry LP 在第三季度新購入了 Eton Pharmaceuticals 的股份，價值約 37,000 美元。Legal &amp; General Group Plc 在第二季度新購入了 Eton Pharmaceuticals 的股份，價值約 41,000 美元。最後，AlphaQuest LLC 在第一季度新購入了 Eton Pharmaceuticals 的股份，價值約 53,000 美元。目前，27.86% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Eton Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Eton Pharmaceuticals 股票表現</h2>
</div><p>NASDAQ ETON opened at $16.57 on Tuesday. The firm's fifty day moving average price is $17.21 and its two-hundred day moving average price is $16.76. The stock has a market cap of $444.41 million, a PE ratio of -66.28 and a beta of 1.17. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.25 and a current ratio of 1.63. Eton Pharmaceuticals has a fifty-two week low of $11.09 and a fifty-two week high of $23.00.</p>
<div class="lb-trans"><p>納斯達克 ETON 週二開盤價為 16.57 美元。該公司的 50 日移動平均價格為 17.21 美元，200 日移動平均價格為 16.76 美元。該股票的市值為 4.4441 億美元，市盈率為-66.28，貝塔值為 1.17。該公司的債務與股本比率為 1.19，速動比率為 1.25，流動比率為 1.63。Eton Pharmaceuticals 的 52 周低點為 11.09 美元，52 周高點為 23.00 美元。</p>
</div><p>Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.20). The firm had revenue of $22.46 million for the quarter, compared to analyst estimates of $20.47 million. Eton Pharmaceuticals had a negative net margin of 9.50% and a negative return on equity of 11.32%. On average, equities analysts expect that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals（納斯達克代碼：ETON - 獲取免費報告）最近於 11 月 6 日發佈了季度財報。該公司報告的每股收益為（0.07）美元，低於共識預期的 0.13 美元（差距為 0.20 美元）。該公司季度收入為 2246 萬美元，而分析師預期為 2047 萬美元。Eton Pharmaceuticals 的淨利潤率為-9.50%，股本回報率為-11.32%。平均而言，股票分析師預計 Eton Pharmaceuticals 在當前財政年度將發佈-0.14 的每股收益。</p>
</div><h2>Eton Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Eton Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals, Inc 是一家專注於開發、生產和商業化針對罕見和服務不足疾病的仿製藥和專有藥品的專業製藥公司。公司總部位於佛羅里達州西棕櫚灘，利用其在激素療法和複雜分子方面的專業知識，解決患者需求高、競爭有限的治療領域。自 2016 年成立以來，Eton 一直致力於建立一個多元化的產品組合，將成熟的仿製藥與針對性品牌產品相結合。</p>
</div><p>The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.</p>
<div class="lb-trans"><p>該公司的產品線包括甲狀腺激素替代品，如干燥甲狀腺和利奧甲狀腺素，以及用於弓形蟲病的吡美莫司片。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Eton Pharmaceuticals</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>The Last Gold Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Eton Pharmaceuticals</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者提醒：微型 “3 美元人工智能奇蹟股票” 即將爆發</li>
<li>資本利得税是否可以扣除任何費用？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>最後的黃金牛市</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVRPTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ETON"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eton Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Eton Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Eton Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Eton Pharmaceuticals 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前立即購買……而 Eton Pharmaceuticals 並不在名單上。</p>
</div><p>While Eton Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Eton Pharmaceuticals 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Eton Pharmaceuticals, Inc.（納斯達克股票代碼：ETON）被券商給予平均 “持有” 評級